• MCC950 Sodium: Advancing NLRP3 Inflammasome Targeting in CNS

  2026-06-25

  Explore the scientific advances of MCC950 sodium in targeting NLRP3 inflammasome activation, with a focus on neuroinflammation, morphine tolerance, and astrocyte phenotypes. Discover unique assay insights and CNS research applications for this selective inhibitor.

• Ser356-Phosphorylated Tau and NUAK Inhibition in Alzheimer’s

  2026-06-24

  Taylor et al. (2023) reveal that tau phosphorylated at serine 356 (p-tau Ser356) is closely associated with Alzheimer’s disease progression and is abundant in neurofibrillary tangles. The study demonstrates that the NUAK inhibitor WZ4003 can selectively reduce p-tau Ser356 in both mouse and human brain tissue, offering new insight for targeted therapeutic strategies.

• STAT5B Overexpression Restores Myelin in Parkinson’s Models

  2026-06-23

  This study uncovers how oligodendrocyte-specific STAT5B overexpression reverses myelin loss and improves motor function in MPTP-induced mouse models of Parkinson’s disease. The findings highlight a DNMT3A-STAT5B-MBP epigenetic axis, offering new insights into the molecular underpinnings of oligodendrocyte dysfunction and neuronal degeneration in PD.

• Cy5 NHS ester(Et): Technical Guidance for Fluorescent Labeli

  2026-06-23

  Cy5 NHS ester(Et) is designed for rapid, high-purity fluorescent labeling of amino groups in proteins and biomolecules, supporting detection and imaging workflows such as immunofluorescence staining, flow cytometry, and fluorescence microscopy. It is not suitable for ethanol-based protocols or for workflows requiring extended storage of dye solutions, and should be used immediately after preparation for optimal results.

• Cediranib (AZD2171): Quantitative Dissection of Angiogenesis

  2026-06-22

  Explore Cediranib (AZD2171) as a precision angiogenesis inhibitor for cancer research, with a unique focus on quantitative assay design and interpretation. This article synthesizes mechanistic insights and recent methodological advances for optimizing VEGFR pathway analysis.

• AICAR and AMPK: Strategic Levers in Translational Metabolic

  2026-06-22

  This article offers translational researchers a mechanistic and strategic guide to leveraging AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) in metabolic disease and inflammation research, with a focus on AMPK-driven pathways, recent breakthroughs in hepatic fibrosis, and practical guidance for robust experimental design. Distinct from conventional product descriptions, it bridges emerging literature, advanced workflows, and future translational opportunities.

• Calcitriol in Advanced Immune & Endometrial Research Workflo

  2026-06-21

  Calcitriol (1,25-dihydroxy vitamin D3) enables precise modulation of immune and reproductive cell signaling in cutting-edge bench research. This guide reveals practical protocols, troubleshooting strategies, and innovative applications—backed by recent findings and APExBIO’s trusted reagent quality.

• Boc-D-FMK: Pan-Caspase Inhibitor for Apoptosis Research Work

  2026-06-20

  Boc-D-FMK stands out as a robust pan-caspase inhibitor, enabling precise control over apoptosis and inflammation pathways in both cell and animal models. This article highlights advanced use-cases, practical protocol enhancements, and troubleshooting strategies that maximize reliability and reproducibility in apoptosis research.

• Dual-Action Kinase Inhibitors Accelerate p38α Dephosphorylat

  2026-06-19

  The reference study uncovers that select kinase inhibitors, by stabilizing inactive conformations of the p38α MAP kinase activation loop, not only inhibit kinase activity but also accelerate its dephosphorylation by phosphatases. This dual-action mechanism offers a new paradigm for achieving enhanced specificity and potency in kinase-targeted research and drug discovery.

• Taxus chinensis Fruit Extract Suppresses Neuroinflammation v

  2026-06-19

  This study demonstrates that Taxus chinensis (Pilg.) Rehder fruit extract (TCFE) significantly attenuates aging-related behaviors and neuroinflammation by suppressing microglial activation through TLR4/NF-κB/NLRP3 pathway modulation. The findings provide molecular evidence for the anti-inflammatory and anti-aging effects of plant-derived compounds, suggesting new avenues for intervention in neurodegenerative and age-associated diseases.

• Prednisone (SKU B2148): Optimizing Immunosuppressive Assays

  2026-06-18

  This article addresses persistent laboratory challenges in cell viability, proliferation, and cytotoxicity workflows, highlighting how Prednisone (SKU B2148) from APExBIO enables reproducible, mechanism-driven results. Drawing on scenario-based Q&A, it provides evidence-backed insights into protocol optimization, data interpretation, and product selection for immunology and neurodegeneration research.

• Demethyleneberberine as a Multi-Pathway Candidate for Huntin

  2026-06-18

  The reference study proposes demethyleneberberine (DMB) as a promising agent for Huntington’s disease (HD), emphasizing its ability to simultaneously inhibit oxidative stress, neuroinflammation, and mitochondrial dysfunction. This mechanistic breadth highlights DMB’s translational potential for modeling and treating neurodegenerative pathways implicated in HD and related disorders.

• Q-VD(OMe)-OPh: Redefining Pan-Caspase Inhibition for Transla

  2026-06-17

  This article delivers a thought-leadership perspective on Q-VD(OMe)-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone), charting its mechanistic underpinnings, experimental validation, and strategic value for translational researchers. It synthesizes recent advances in apoptosis modulation, competitive benchmarking, and workflow guidance, while drawing on landmark studies and internal content to push the conversation beyond conventional product summaries.

• Strategic PKA Inhibition: H 89 2HCl in Translational Signali

  2026-06-17

  This article explores how H 89 2HCl empowers translational researchers to dissect the cAMP/PKA signaling pathway, with mechanistic insights from neurobiology and bone remodeling. It integrates recent findings on dopamine-mediated osteoclast regulation, offers protocol guidance, and positions H 89 2HCl as an industry gold standard for precision kinase inhibition. Distinct from standard product pages, this thought-leadership piece bridges molecular mechanism, workflow strategy, and future research impact.

• Sunitinib: Multi-Targeted RTK Inhibitor for Cancer Research

  2026-06-16

  Sunitinib is a potent multi-targeted receptor tyrosine kinase inhibitor used in cancer research, particularly for renal cell carcinoma. It acts by blocking VEGFRs, PDGFRs, and related pathways involved in tumor angiogenesis and proliferation. Recent studies show its efficacy can be enhanced through combination strategies targeting cell death pathways.

444 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page